Header

UZH-Logo

Maintenance Infos

Personalized cancer medicine and the future of pathology


Moch, H; Blank, P R; Dietel, M; Elmberger, G; Kerr, K M; Palacios, J; Penault-Llorca, F; Rossi, G; Szucs, T D (2012). Personalized cancer medicine and the future of pathology. Virchows Archiv, 460(1):3-8.

Abstract

In February 2011, a group of pathologists from different departments in Europe met in Zurich, Switzerland, to discuss opportunities and challenges for pathology in the era of personalized medicine. The major topics of the meeting were assessment of the role of pathology in personalized medicine, its future profile among other biomedical disciplines with an interest in personalized medicine as well as the evolution of companion diagnostics. The relevance of novel technologies for genome analysis in clinical practice was discussed. The participants recognize that there should be more initiatives taken by the pathology community in companion diagnostics and in the emerging field of next-generation sequencing and whole genome analysis. The common view of the participants was that the pathology community has to be mobilized for stronger engagement in the future of personalized medicine. Pathologists should be aware of the challenges and the analytical opportunities of the new technologies. Challenges of clinical trial design as well as insurance and reimbursement questions were addressed. The pathology community has the responsibility to lead medical colleagues into embracing this new area of genomic medicine. Without this effort, the discipline of pathology risks losing its key position in molecular tissue diagnostics.

Abstract

In February 2011, a group of pathologists from different departments in Europe met in Zurich, Switzerland, to discuss opportunities and challenges for pathology in the era of personalized medicine. The major topics of the meeting were assessment of the role of pathology in personalized medicine, its future profile among other biomedical disciplines with an interest in personalized medicine as well as the evolution of companion diagnostics. The relevance of novel technologies for genome analysis in clinical practice was discussed. The participants recognize that there should be more initiatives taken by the pathology community in companion diagnostics and in the emerging field of next-generation sequencing and whole genome analysis. The common view of the participants was that the pathology community has to be mobilized for stronger engagement in the future of personalized medicine. Pathologists should be aware of the challenges and the analytical opportunities of the new technologies. Challenges of clinical trial design as well as insurance and reimbursement questions were addressed. The pathology community has the responsibility to lead medical colleagues into embracing this new area of genomic medicine. Without this effort, the discipline of pathology risks losing its key position in molecular tissue diagnostics.

Statistics

Citations

Dimensions.ai Metrics
25 citations in Web of Science®
30 citations in Scopus®
57 citations in Microsoft Academic
Google Scholar™

Altmetrics

Downloads

2 downloads since deposited on 03 Jan 2012
0 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, further contribution
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Institute of Pathology and Molecular Pathology
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:2012
Deposited On:03 Jan 2012 16:05
Last Modified:22 Sep 2018 04:09
Publisher:Springer
ISSN:0945-6317
OA Status:Green
Publisher DOI:https://doi.org/10.1007/s00428-011-1179-6
PubMed ID:22143935

Download

Filetype: Other (Coversheet Pages conversion from application/pdf to application/pdf) - Registered users only
Download PDF  'Personalized cancer medicine and the future of pathology'.
Preview
Content: Published Version
Language: English
Filetype: PDF (Nationallizenz 142-005)
Size: 244kB